IP Library › Granted Patent US 12,385,061
Granted Patent B2
US 12,385,061 · App. 16/640,788 · Granted Aug 12, 2025

Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression

Inventors: Eric M. Ostertag (San Diego, CA); Devon Shedlock (San Diego, CA)
Assignee: Poseida Therapeutics, Inc.
C12N15/85A61K40/11A61K40/31A61K40/40A61K40/4215A61P7/04C07K14/7051C07K16/2878C12N9/003C12N9/644C12Y105/01003C12Y304/21022C07K2319/02C07K2319/03C12N2830/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,385,061
App. No.
16/640,788
Granted
Aug 12, 2025
Kind
B2
Abstract

Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the construct of (b) into a genomic sequence of a cell, the exogenous reporter is expressed, and wherein the exogenous reporter, upon binding a ligand, transduces an intracellular signal that targets the inducible promoter of (a) to modify gene expression. Methods for introducing compositions into cells and the use of the resultant cells in adoptive cell therapies are also provided.

Claims (19)

1. A method of expressing a transgene comprising:

a) providing a population of T-cells wherein a plurality of T-cells in the population comprise at least one chimeric antigen receptor (CAR) and at least one inducible transgene construct,

wherein the CAR is a transmembrane protein comprising (i) an ectodomain comprising a a signal peptide and a ligand recognition region, wherein the ligand recognition region comprises at least one scaffold protein; (ii) a transmembrane domain; and (iii) an endodomain comprising at least one costimulatory domain,

wherein the at least one inducible transgene construct comprises a sequence encoding an NFκB-inducible promoter and a transgene; and

b) contacting the population of T-cells with a ligand that binds to the ligand recognition region of the at least one CAR,

wherein upon binding of the ligand to the ligand recognition region, the endodomain of the at least one CAR transduces an intracellular signal that targets the NFκB-inducible promoter and results in expression of the transgene within the plurality of T-cells.

2. The method of claim 1 , wherein the ectodomain of (i) further comprises a hinge between the ligand recognition region and the transmembrane domain.

3. The method of claim 1 , wherein the at least one scaffold protein comprises an antibody, an antibody fragment, a single domain antibody, a single chain antibody, an antibody mimetic, a single chain variable fragment (scFv), a VH, a VHH or a Centyrin.

4. The method of claim 1 , wherein the CAR specifically binds to BCMA or MUC-1.

5. The method of claim 1 , wherein the transgene comprises a sequence that is endogenous with respect to the genomic sequence of the T-cell.

6. The method of claim 1 , wherein the transgene comprises a sequence that is exogenous with respect to the genomic sequence of the T-cell.

7. The method of claim 6 , wherein the exogenous sequence is a synthetic, modified, recombinant, chimeric or non-naturally occurring sequence with respect to the genome of the cell.

8. The method of claim 1 , wherein the transgene encodes a secreted protein.

9. The method of claim 8 , wherein the secreted protein is Factor IX.

10. The method of claim 1 , wherein, the signal peptide comprises a sequence encoding a human CD2, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD8α, CD19, CD28, 4-1BB or GM-CSFR signal peptide.

11. The method of claim 1 , wherein the transmembrane domain comprises a sequence encoding a human CD2, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD8α, CD19, CD28, 4-1BB or GM-CSFR transmembrane domain.

12. The method of claim 1 , wherein the endodomain comprises a human CD3ζ endodomain.

13. The method of claim 1 , wherein the at least one costimulatory domain comprises a human 4-1BB, CD28, CD40, ICOS, MyD88, OX-40 intracellular segment, or any combination thereof.

14. The method of claim 1 , wherein the NFκB-inducible promoter comprises 1, 2, 3, 4 or 5 repeats of the NFκB response element.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: OSTERTAG, ERIC M.; SHEDLOCK, DEVON
To: POSEIDA THERAPEUTICS, INC.
Reel/Frame 058266/0138 →
Continuity (2)
Provisional Application 62556310 · Sep 8, 2017
Related Publication 20210130845A1 · May 6, 2021
References Cited (153)
US 4309989A · Fahim · 1982 [cited by applicant]
US 4656134A · Ringold · 1987 [cited by applicant]
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4704692A · Ladner · 1987 [cited by applicant]
US 4766067A · Biswas · 1988 [cited by applicant]
US 4767402A · Kost et al. · 1988 [cited by applicant]
US 4795699A · Tabor et al. · 1989 [cited by applicant]
US 4800159A · Mullis et al. · 1989 [cited by applicant]
US 4818542A · DeLuca et al. · 1989 [cited by applicant]
US 4889818A · Gelfand et al. · 1989 [cited by applicant]
US 4921794A · Tabor et al. · 1990 [cited by applicant]
US 4939666A · Hardman · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 4965188A · Mullis et al. · 1990 [cited by applicant]
US 4994370A · Silver et al. · 1991 [cited by applicant]
US 5066584A · Gyllensten et al. · 1991 [cited by applicant]
US 5091310A · Innis · 1992 [cited by applicant]
US 5122464A · Wilson et al. · 1992 [cited by applicant]
US 5130238A · Malek et al. · 1992 [cited by applicant]
US 5142033A · Innis · 1992 [cited by applicant]
US 5168062A · Stinski · 1992 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5260203A · Ladner et al. · 1993 [cited by applicant]
US 5266491A · Nagata et al. · 1993 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5427908A · Dower et al. · 1995 [cited by applicant]
US 5455030A · Ladner et al. · 1995 [cited by applicant]
US 5518889A · Ladner et al. · 1996 [cited by applicant]
US 5534621A · Ladner et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5576195A · Robinson et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5580734A · Treco et al. · 1996 [cited by applicant]
US 5595898A · Robinson et al. · 1997 [cited by applicant]
US 5618920A · Robinson et al. · 1997 [cited by applicant]
US 5641670A · Treco et al. · 1997 [cited by applicant]
US 5643768A · Kawasaki · 1997 [cited by applicant]
US 5656730A · Lee · 1997 [cited by applicant]
US 5658754A · Kawasaki · 1997 [cited by applicant]
US 5693493A · Robinson et al. · 1997 [cited by applicant]
US 5698417A · Robinson et al. · 1997 [cited by applicant]
US 5698435A · Robinson et al. · 1997 [cited by applicant]
US 5733761A · Treco et al. · 1998 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5763733A · Whitlow et al. · 1998 [cited by applicant]
US 5767260A · Whitlow et al. · 1998 [cited by applicant]
US 5770359A · Wilslon et al. · 1998 [cited by applicant]
US 5827739A · Wilson et al. · 1998 [cited by applicant]
US 5837500A · Ladner et al. · 1998 [cited by applicant]
US 5839446A · Waner et al. · 1998 [cited by applicant]
US 5851198A · Castellano et al. · 1998 [cited by applicant]
US 5856456A · Whitlow et al. · 1999 [cited by applicant]
US 5885793A · Griffiths et al. · 1999 [cited by applicant]
US 6019968A · Platz et al. · 2000 [cited by applicant]
US 8556882B2 · Morgan et al. · 2013 [cited by applicant]
US 9228180B2 · Izsvak et al. · 2016 [cited by applicant]
US 9393292B2 · Brenner · 2016 [cited by applicant]
US 9913882B2 · Slawin et al. · 2018 [cited by applicant]
US 10041077B2 · Minshull et al. · 2018 [cited by applicant]
US 20120270300A1 · Enjolras · 2012 [cited by examiner]
US 20180244797A1 · Pulé · 2018 [cited by examiner]
US 20200095573A1 · Wei · 2020 [cited by examiner]
WO WO9117271A1 · 1991 [cited by applicant]
WO WO9118980A1 · 1991 [cited by applicant]
WO WO9119818A1 · 1991 [cited by applicant]
WO WO9205258A1 · 1992 [cited by applicant]
WO WO9214843A1 · 1992 [cited by applicant]
WO WO9308278A1 · 1993 [cited by applicant]
WO WO9619256A1 · 1996 [cited by applicant]
WO WO9853847A1 · 1998 [cited by applicant]
WO WO9916419A1 · 1999 [cited by applicant]
WO WO2006133398A2 · 2006 [cited by applicant]
WO WO2013049275A1 · 2013 [cited by applicant]
WO WO2013123503A1 · 2013 [cited by applicant]
WO WO2015123642A1 · 2015 [cited by applicant]
WO WO2017023801A1 · 2017 [cited by applicant]
WO WO2017147538A1 · 2017 [cited by applicant]
WO WO2017133633A1 · 2017 [cited by applicant]
WO WO2018073394A1 · 2018 [cited by examiner]
WO WO2018213332A1 · 2018 [cited by applicant]
WO WO2019014390A1 · 2019 [cited by applicant]
WO WO2019051424A9 · 2019 [cited by applicant]
WO WO2020051374A1 · 2020 [cited by applicant]
US 5,733,746 A, 03/1998, Treco et al. (withdrawn) [cited by applicant]
Chica et al. Curr Opin Biotechnol. Aug. 2005;16(4):378-84. (Year: 2005). [cited by examiner]
Singh et al. Curr Protein Pept Sci. 2017, 18, 1-11 (Year: 2017). [cited by examiner]
Chmielewski, M. and Abken, H. (Dec. 12, 2017) “CAR T Cells Releasing IL-18 Convert to T-Bet [cited by applicant]
Kulemzin, S.V. et al. (Mar. 13, 2019) “Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines” BMC Medical Genomics, 12(Suppl 2):44, doi.org/10.1186/… [cited by applicant]
Liu, Y. et al. (Jul. 2019) “Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma” J Immunol, 203(1):198-207. [cited by applicant]
Moghimi, B. et al. (2021) “Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma” Nat Commun, 12:511; doi.org/10.1038/s41467-020-20785-x, 15 pages. [cited by applicant]
Roybal, K.T. et al. (Oct. 6, 2016) “Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors” Cell, 167(2):P419-432,E16; doi.org/10.1016/j.cell.2016.09.011, 31 pages. [cited by applicant]
Uchibori, R. et al. (Mar. 2, 20199) “Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen Receptor” Mol Ther Oncolytics, 12:16-25. [cited by applicant]
Zhang, L. et al. (May 2015) “Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma” Clin Cancer Res, 21(10):2278-2288. [cited by applicant]
Zimmerman, K. et al. (Feb. 6, 2020) “Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines” Cancers, 12(2):375; doi: 10.3390/cance… [cited by applicant]
Nakagawa, T., et al. (2013) “Development of next-generation adoptive immunotherapy using chimeric antigen receptor (CAR)-expressing cytotoxic T cells (CTL),” Drug Delivery System, 28(1): 35-44, English abstract only. [cited by applicant]
Higuchi, Y. (2013) “Development of optical imaging to visualize dynamics of cells in vivo” Drug Delivery System, 28(1):17-23. [cited by applicant]
Ando, M. and Nakauchi, H. (Mar. 1, 2017) “‘Off-the-shelf’ immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes”, Experimental Hematology, 47:2-12. [cited by applicant]
Arcone, R. et al. (1988) “Identification of sequences responsible for acute-phase induciton of human C-reactive protein” Nucl Acids Res, 16(8):3195-3207. [cited by applicant]
Bojak, A. et al. (2002) “Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis” Vaccine, 20:1975-1979. [cited by applicant]
Cazeaux, N. et al. (2002) “Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter” Vaccine, 2… [cited by applicant]
Cunningham, B.C. and J.A. Wells (Jun. 2, 1989) “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis” Science, 244:1081-1085. [cited by applicant]
De Vos, A.M. et al. (1992) “Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex” Science, 255:306-312. [cited by applicant]
Donnelly, J.J. et al. (1997) “DNA Vaccines” Annu Rev Immunol, 15:617-648. [cited by applicant]
GenBank Accession No. AB 179012.1 (Oct. 6, 2006) “Macaca fascicularis testis cDNA clone: QtsA-11460, similar to human piggyBac transposable element derived 3 (PGBD3), mRNA, RefSeq: NM_170753.1” Bethesda (MD): National L… [cited by applicant]
GenBank Accession No. EU287451.1 (Mar. 1, 2008) “Macdunnoughia crassisigna transposon piggyBac McrPLE, complete sequence” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [… [cited by applicant]
GenBank Accession No. GU270322.1 (Jan. 19, 2010) “Pectinophora gossypiella transposon piggyBac-like element PgPLE1.1 transposase gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for … [cited by applicant]
GenBank Accession No. GU329918.1 (Dec. 31, 2010) “Aphis gossypii transposon piggyBac-like element AgoPLE1. 1 transposase gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for Biotechn… [cited by applicant]
GenBank Accession No. GU477713.1 (Mar. 8, 2011) “Ctenoplusia agnata transposon piggyBac-like element PLE1.1 transposase gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for Biotechno… [cited by applicant]
GenBank Accession No. GU477714.1 (Mar. 8, 2011) “Agrotis ipsilon transposon piggyBac-like element PLE1.1 transposase gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnolog… [cited by applicant]
GenBank Accession No. JX294476.1 (Jan. 30, 2015) “Chilo suppressalis transposon piggyBac-like element transposase (PLE1.1) gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for Biotec… [cited by applicant]
GenPept Accession No. AAA87375.2 (Oct. 15, 2002) “unknown protein [Trichoplusia ni]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: https://www.… [cited by applicant]
GenPept Accession No. AAL39784.1 (Dec. 1, 20017) “LD40589p [ [cited by applicant]
GenPept Accession No. AAM76342.1 (Dec. 20, 2002) “putative transposase [Daphnia pulicaria]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: https… [cited by applicant]
GenPept Accession No. ABD76335.1 (Aug. 3, 2006) “transposase [Heliothis virescens]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: https://www.n… [cited by applicant]
GenPept Accession No. ABS18391.1 (Mar. 17, 2008) “transposase [Helicoverpa armigera]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: https://www… [cited by applicant]
GenPept Accession No. BAD11135.1 (Sep. 15, 2007) “putative transposase yabusame-1 [Bombyx mori]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: … [cited by applicant]
GenPept Accession No. BAF82026.1 (Sep. 9, 2008) “piggyBac transposase Uribo2 [Xenopus tropicalis]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from… [cited by applicant]
GenPept Accession No. NP_689808.2 (May 2, 2019) “piggyBac transposable element-derived protein 4 [ [cited by applicant]
GenPept Accession No. NP_741958.1 (Mar. 29, 2020) “piggyBac transposable element-derived protein 5 [Mus musculus]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]… [cited by applicant]
GenPept Accession No. XP_001814566.1 (Jul. 21, 2008) “Predicted: similar to PiggyBac transposable element-derived protein 4 [Tribolium castaneum]” Bethesda (MD): National Library of Medicine (US), National Center for Bi… [cited by applicant]
GenPept Accession No. XP_001948139.1 (Jul. 2, 2008) “Predicted: similar to Piggy Bac transposable element-derived protein 4 [Acyrthosiphon pisum]” Bethesda (MD): National Library of Medicine (US), National Center for Bi… [cited by applicant]
GenPept Accession No. XP_002123602.1 (Oct. 24, 2014) “Predicted: piggyBac transposable element-derived protein 4-like [Ciona intestinalis]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechno… [cited by applicant]
GenPept Accession No. XP_220453.3 (Apr. 15, 2005) “Predicted: similar to piggyBac transposable element derived 2 [Rattus norvegicus]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology I… [cited by applicant]
GenPept Accession No. XP_310729.1 (Apr. 26, 2018) “AGAP000379-PA [Anopheles gambiae str. PEST]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: h… [cited by applicant]
GenPept Accession No. XP_312615.1 (Apr. 26, 2018) “AGAP002349-PA [Anopheles gambiae str. PEST]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: h… [cited by applicant]
GenPept Accession No. XP_320414.1 (Apr. 2, 20186) “AGAP012114-PA [Anopheles gambiae str. PEST]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: h… [cited by applicant]
Gossen, M. and H. Bujard (Jun. 1992) “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters” Proc Natl Acad Sci USA, 89:5547-5551. [cited by applicant]
Gossen, M. et al. (Jun. 23, 1995) “Transcriptional activation by tetracyclkines in mammalian cells” Science, 268(5218):1766-1769. [cited by applicant]
Irving, M. et al. (Apr. 3, 2017) “Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel” Frontiers in Immunology, 8:267, 19 pages. [cited by applicant]
Iuliucci, J.D. et al. (2001) “Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers” J Clin Pharmacol, 41:870-879. [cited by applicant]
Jena, B. et al. (Aug. 19, 2010) “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor” Blood, 116(7):1035-1044. [cited by applicant]
Junginger, H.E. et al. (1994) “Visualization of Drug Transport Across Human Skin and the Influence of Penetration Enhancers” in Drug Permeation Enhancement. Hsieh, D.S. (Ed.); New York: Marcel Dekker, Inc., pp. 59-89. [cited by applicant]
Kageyama, R. et al. (Feb. 1, 19875) “Differing Utilization of Homologous Transcription Initiation Sites of Rat K and T Kininogen Genes Under Inflammation Condition” J Biol Chem, 262(5):2345-2351. [cited by applicant]
Maus, M. V. et al. (Apr. 2, 20144) “Antibody-modified T cells: CARs take the front seat for hematologic malignancies” Blood, 123(17):2625-2635. [cited by applicant]
Myers, D.R. et al. (2017) “Tonic Signals: Why do Lymphocytes Bother?” Trends in Immunology, Article in Press [online]. Retrieved from: http://dx.doi.org/10.1016/j.it.2017.06.010, 14 pages. [cited by applicant]
Oliviero, S. et al. (1987) “The human haptoglobin gene: transcriptional regulation during development and acute phase induction” The EMBO Journal, 6(7):1905-1912. [cited by applicant]
Philip, B et al. (Aug. 21, 2014) “A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy” Blood, 124(8):1277-1287. [cited by applicant]
Poli, V. and R. Cortese (Nov. 1989) “Interleukin 6 induces a liver-specific nuclear protein that binds to the promoter of acute-phase genes” Proc Natl Acad Sci USA, 86:8202-8206. [cited by applicant]
Prowse, K.R. and H. Baumann (Jan. 1988) “Hepatocyte-Stimulating Factor, β2 Interferon, and Interleukin-1 Enhance Expression of the Rat α1-Acid Glycoprotein Gene via a Distal Upstream Regulatory Region” Mol Cell Biol, 8(… [cited by applicant]
Quntarelli, C et al. (Oct. 15, 2007) “Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes” Blood, 110(8):2793-2802 [online]. Retrieved from the Intern… [cited by applicant]
Smith, L.J. et al. (1992) “Human Interleukin 4. The Solution Structure of a Four-helix Bundle Protein” J Mol Biol, 244:899-904. [cited by applicant]
Sprague, J. et al. (Feb. 1983) “Expression of a Recombinant DNA Gene Coding for the Vesicular Stomatitis Virus Nucleocapsid Protein” J Virol, 45(2):773-781. [cited by applicant]
Straathof, K.C. et al. (2005) “An inducible caspase 9 safety switch for T-cell therapy” Blood, 105:4247-4254. [cited by applicant]
Uchibori, R. et al. (May 1, 2014) “Development of inducible switch promoters that drive exogenous gene expression upon the recognition of CD19 by chimeric antiven receptors” Molecular Therapy, 22(Suppl 1):S165-S166, Abs… [cited by applicant]
Vilaboa, N. et al. (Jan. 1, 2011) “Gene Switches for Deliberate Regulation of Transgene Expression: Recent Advances in System Development and Uses”, J Genet Syndr Gene Ther, 2(3):1000107; DOI: 10.4172/2157-7412.1000107,… [cited by applicant]
Wilson, D.R. et al. (Dec. 1990) “A 58-Base-Pair Region of the Human C3 Gene Confers Synergistic Inducibility by Interleukin-1 and Interleukin-6” Mol Cell Biol, 10(12):6181-6191. [cited by applicant]
Wu, C-Y. et al. (Oct. 16, 2015) “Remote control of therapeutic T cells through a small molecule-gated chimeric receptor” Science, 350(6258); DOI: 10.1126/science.aab4077, 10 pages, with Summary, p. 293. [cited by applicant]
Zechner, R. et al. (Jun. 1988) “Recombinant Human Cachectin/Tumor Necrosis Factor but Not Interleukin-1α Downregulates Lipoprotein Lipase Gene Expression at the Transcriptional Level in Mouse 3T3-L1 Adipocytes” Mol Cell… [cited by applicant]
Li, Haiying et al. “Modern Molecular Biology and Genetic Engineering” General Higher Education “Eleventh Five-Year Plan”, Beijing: Chemical Industry Press (2008); p. 95, in Chinese only, 3 pages, ISBN 978-7-122-01794-9. [cited by applicant]
Luo, Senlin et al. “Bioinformation Processing Techniques and Methods” Beijing: Beijing Institute of Technology Press (2015); p. 300, in Chinese only, 16 pages. [cited by applicant]
Office Action for Chinese Application No. 201880071587.1 mailed Sep. 30, 2024, 15 pages. [cited by applicant]